Stock Control through Video Surveillance in Logistics

Maria E. Carullo,G. Cavaliere,Aniello De Prisco,M. D. Capua,A. Petrosino,Donatella Padovano,Gennaro Nave,D. Ruggeri

DOI: https://doi.org/10.1007/978-3-642-41184-7_75

2013-09-09

Abstract:

What problem does this paper attempt to address?

Multifocal Lateral and Fourth Ventricular Primary Central Nervous System Lymphoma: Case Report and Literature Review.

Yu Zhu,Ke Ye,Renya Zhan,Ying Tong

DOI: https://doi.org/10.5137/1019-5149.jtn.10496-14.1

2015-01-01

Turkish Neurosurgery

Abstract:We report a 66-year-old man with 2-month history of dizziness and 1-month history of diplopia. Cranial magnetic resonance imaging (MRI) disclosed two solid masses, one in the right lateral ventricle and another in the fourth ventricle. A surgical biopsy was performed on the basis of safety. The diagnosis of large B-cell lymphoma was made postoperatively. The patient recovered without additional deficits and was then commenced on chemotherapy and remained well 6 months after the diagnosis. Primary B-cell lymphomas should always be included in the list of differential diagnosis of intraventricular tumors. Here we report an extremely rare case of primary central nervous system lymphoma with multifocal ventricular involvement.
A rare type of left atrial dissection.

M. Ninomiya,Tsuyoshi Taketani,T. Ohtsuka,N. Motomura,S. Takamoto

DOI: https://doi.org/10.1067/MTC.2002.124235

IF: 6.439

2002-09-01

Journal of Thoracic and Cardiovascular Surgery

Abstract:Left atrial dissection after mitral valve repair is a rare complication, and transesophageal echocardiography (TEE) is reported to be decisive for its diagnosis.1-4 We encountered an unreported type of left atrial dissection after mitral valve replacement and the maze procedure, which had a delayed onset, located mainly in the anterior side of the left atrium, and was spontaneously cured without surgical treatment.
Accounting for voice-quality variation

N. Campbell

DOI: https://doi.org/10.21437/speechprosody.2004-50

2004-03-23

Abstract:A computer system architecture includes microcell computing units with a moving memory distribution of data and instructions to the microcells which are connected to users and other peripheral devices via a telephony type of cell access switch. The computing microcell can be a single computing element or can be a nucleus processor which is connected to a number of satellite processors via a bus or star configuration, and which interfaces with the moving memory modules and cell access switch. The moving memory modules are functionally petitioned to include user's files for data, and operating system instructions, and journal files and reservation files, all of which repetitively broadcast the contents of memory via a moving memory bus within dissimilar repetition intervals.
[Rabies specific IgM- and IgG-antibody response in persons immunized with HDCS vaccine according to the Essen postexposure vaccination schedule (author's transl)].

O. Thraenhart,E. Kuwert

1979-12-01

Abstract:A solid phase enzyme immunoassay (ELISA) was applied for the determination of rabies virus antibodies of the immunoglobulin classes G and M in sera of 10 young adults. Vaccinations were carried out with the Essen post-exposure vaccination schedule, which is recommended by the W.H.O., with the rabies HDCS vaccine with an antigen value of 1.9. From these results the rabies virus IgM/IgG-conversion was derived. Furthermore a comparison was carried out of results obtained with the ELISA, the mouse neutralization test, the complement fixation test and the hemagglutination inhibition test. Rabies virus-IgM-antibodies were detected already three days after the first vaccination. The IgM-antibody concentration increased to a maximum at the 22nd day p.v. In sera of seven of eight vaccinees rabies virus IgM-antibody was still detectable until the 90th day p.v. Rabies virus antibodies of the IgG-class were found in the serum of 1/7 vaccinees at the 7th day p.v. A steep increase of the rabies virus IgG-antibodies was observed from day 10 p.v. to a maximum between the 30th and 40th day p.v.. The titer values varied between 1:10-1:1600. The rabies virus IgM/IgG-conversion was observed after the 10th day p.v.. More than 75% of the total antirabies virus globulin fraction belonged to the IgG-class in sera of 6 of 9 vaccinees between the 22nd and 30th day of p.v.. A preponderance of the rabies virus IgM-antibodies was seen in 3 of 9 vaccinees until the 90th day p.v.. Most sensitive for the early detection of rabies virus antibodies was the IgM-ELISA followed by the IgG-ELISA, mouse-neutralization test, hemagglutination inhibition test and complement fixation test.
Treatment Outcomes of Low-grade Lymphoma of the Orbit

C L Holloway,T Pickles,N S Croteau,E S Wai

DOI: https://doi.org/10.1016/j.clon.2022.01.042

Abstract:Aims: Radiation therapy can be used with curative intent in patients with low-grade orbital non-Hodgkin's lymphoma (NHL) stages IE and IVE (limited to the bilateral orbits). This study evaluated local control and survival outcomes of patients with unilateral or bilateral orbital lymphoma treated in a provincial population. Materials and methods: The study subjects were 176 patients with low-grade orbital or conjunctival lymphoma referred for management from 1980 to 2016. Demographic, tumour and treatment characteristics were abstracted by chart review. Recurrence-free survival (RFS) and overall survival were assessed with competing risks analysis and Gray's test. Results: The median follow-up was 8.5 years (range 0.4-29.5 years). The median age at diagnosis was 65 years (range 20-97 years). The most common histological subtype was mucosa-associated lymphoid tissue (MALT) (73%). Stage IVE accounted for 20.5% of the cohort. Orbital radiation therapy was used in 122 patients with stage IE (87%) and 12 patients with stage IVE (28%). The median dose was 25 Gy (range 2-35 Gy). Other treatments were antibiotics (seven patients), chemotherapy (10 patients), radioimmunotherapy (six patients), surgery (three patients) and observation (16 patients). Within the group treated with orbital external beam radiation therapy (EBRT) there were no local recurrences. Among those with stage IE NHL, EBRT was associated with improved local RFS (P ≤ 0.001) but did not have an impact on contralateral or distant RFS. In patients with stage IVE NHL limited to the bilateral orbit, bilateral EBRT was associated with improved RFS (P = 0.012) but did not affect distant recurrences or overall survival. Conclusion: There were no local recurrences after EBRT for stage IE and IVE orbital low-grade NHL. The treatments offered over the study period varied, but only EBRT for stage IVE disease improved RFS. This supports EBRT as the preferred primary treatment for patients with localised orbital low-grade lymphoma, including those with bilateral disease.
Introducing Brian Boycott and Heinz Wassle, the 1999 recipients of the proctor medal.

G. Westheimer

1999-06-01

Investigative Ophthalmology and Visual Science

Abstract:
Ultra-low dose radiotherapy in the management of low-grade orbital lymphomas

Bárbara de Castro,Rita Pinho Peixeiro,José Mário Mariz,Ângelo Oliveira

DOI: https://doi.org/10.5603/RPOR.a2022.0044

2022-07-29

Abstract:Background: Ultra-low dose radiotherapy (ULDRT) (2 × 2 Gy) has been used for symptomatic control of low-grade lymphomas with surprising local control rates, suggesting that these entities could respond to lower doses. These are particularly desirable for the treatment of orbital sites and some publications refer to high rates of complete responses. In this paper, we present our experience with the use of ULDRT for indolent orbital lymphomas. Materials and methods: Electronic files and treatment plans of patients treated with ULDRT for low-grade orbital lymphoma were retrospectively reviewed. Oncological outcomes and toxicities were collected and described for each patient. Results: Seven patients (median age of 75 years) with 8 lesions (3 follicular, 2 MALT, 1 marginal and 1 low-grade non-Hodgkin lymphoma) were considered for analysis. The majority had stage IE disease and one patient had bilateral disease. Six tumors were detected on imaging (median size of 20 mm). Involved orbital sites were periocular, conjunctival and palpebral; there was one case of intraocular (choroid) and one case of lacrimal gland involvement. One patient received consolidative rituximab after RT. The median follow-up time was 22 months. Two patients had partial response, one of them with persistent minimal choroidal disease and the other with partial response on CT. Five (71%) patients had clinical (n = 2) or radiologic (n = 3) complete response on treated sites. Reported late toxicities were minimal and included dry eye and pruritus. Conclusion: In our experience, ULDRT achieved a local control rate of 100% and complete response rate of 71% with minimal toxicity.
POSSIBLE DANGER OF ASPIRIN THERAPY IN PRESENCE OF MIGRAINE

I. Bone,W. Durward,ValerieM.D. Hind

DOI: https://doi.org/10.1016/S0140-6736(78)92790-3

IF: 202.731

1978-09-23

The Lancet

Abstract:
Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?

T. Mikuls,K. Saag

DOI: https://doi.org/10.1007/S11926-996-0046-Y

2005-06-01

Current Rheumatology Reports

Abstract:
[Secondary orbital lymphoma]

I Basanta,C Sevillano,M D Álvarez

DOI: https://doi.org/10.1016/j.oftal.2014.07.013

Abstract:Case report: A case is presented of an 85 year-old Caucasian female with lymphoma that recurred in the orbit (secondary ocular adnexal lymphoma). The orbital tumour was a diffuse large B-cell lymphoma according to the REAL classification (Revised European-American Lymphoma Classification). Discussion: Orbital lymphomas are predominantly B-cell proliferations of a variety of histological types, and most are low-grade tumours. Patients are usually middle-aged or elderly, and it is slightly more common in women. A palpable mass, proptosis and blepharoptosis are the most common signs of presentation.
Orbital metastasis from thyroid cancer: a case report and review of the literature

Giulia Sapuppo,Federica Martorana,Elena Tirrò,Rosario Le Moli,Romilda Masucci,Lelio Baldeschi,Corrado Spatola,Antonino Belfiore,Paolo Vigneri,Gabriella Pellegriti

DOI: https://doi.org/10.21037/apm-22-61

Abstract:Background: Differentiated thyroid cancer (DTC) is generally associated with an excellent prognosis. However up to 20% of DTC patients have disease events during subsequent follow-up; rarely patients present an aggressive disease with distant metastases (DM), mainly in the lung and bone. Metastases at unusual sites may also occur, generally in patients with disseminated disease. Orbital localization is rare and only few cases have been described so far. Case description: A 36 years-old man, treated with chemo and radiotherapy during childhood for non-Hodgkin lymphoma, was referred for suspicious lymph node (LN) and multiple lung metastases. Total thyroidectomy and latero-cervical (LC) lymphadenectomy were performed: papillary thyroid cancer (PTC), 25 mm, 11/17 LN metastases; pT2N1bM1. Post-treatment total body scan with I-131 showed LN and lung uptake. Eighteen months from diagnosis he presented progressive diplopia, proptosis and right exophthalmos due to an 18 mm orbital metastasis. Hence, due to I-131 refractoriness for structural disease progression despite I-131 therapy, he started therapy with Lenvatinib for 6 months, with initial partial response followed by disease progression, and then with Cabozantinib, which he stopped after 6 months for adverse events and disease progression after therapy reduction. Currently, the patient is receiving Lenvatinib, rechallenge therapy, with disease stabilization and biochemical response. Molecular analysis, performed on both primary and relapsed tumor didn't show any significant pathogenic alteration. Conclusions: This case of DTC with an unusual metastasis in the orbit, may suggest that patient's exposure to chemo- and radiotherapy during pediatric age might have played a role in the subsequent development of this unusually aggressive tumor, reinforcing the recommendation of long-term and intensive follow-up of these patients.
Orbital lymphoma

Tine Gadegaard Olsen,Steffen Heegaard

DOI: https://doi.org/10.1016/j.survophthal.2018.08.002

Abstract:Orbital lymphomas constitute 50-60% of ocular adnexal lymphomas. A total of 2211 cases of orbital lymphoma with a known subtype have been reported in the last 24 years (1994-2017). The vast majority of orbital lymphomas are of B-cell origin (97%), of which extranodal marginal zone B-cell lymphoma (EMZL) (59%) is the most common subtype, followed by diffuse large B-cell lymphoma (23%), follicular lymphoma (9%), and mantle cell lymphoma (5%). Orbital lymphoma is primarily a disease of the elderly. Gender distribution varies according to lymphoma subtype. However, extranodal marginal zone B-cell lymphoma (53%) and follicular lymphoma (75%) show a female predominance, whereas diffuse large B-cell lymphoma shows an even gender distribution. Mantle cell lymphoma has a striking male predominance of 80%. The histopathological subtype and the clinical stage of the disease are the best indicators of prognosis and patient outcome. Low-grade lymphomas such as extranodal marginal zone B-cell lymphoma and FL have a good prognosis, whereas high-grade lymphomas (diffuse large B-cell lymphoma and mantle cell lymphoma) are associated with a poor prognosis. When managing solitary low-grade lymphomas, radiotherapy is the treatment of choice. Chemotherapy, with or without radiotherapy, should be chosen for disseminated and high-grade lymphomas.
Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection.

M. Vieyra,Staci Leisman,Hugo Raedler,Wing-hong Kwan,Min Yang,M. Strainic,M. Medof,P. Heeger

DOI: https://doi.org/10.1016/j.ajpath.2011.04.038

IF: 5.77

2011-08-01

American Journal Of Pathology

Abstract:
Ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study

Xiaolu Yang,Ruonan Wang,Xiaochun Yuan,Shengyu Yao,Chungang Wang,Jinwei Cheng

DOI: https://doi.org/10.1186/s13014-022-02180-6

2022-12-20

Abstract:Purpose: This single-arm, prospective, exploratory study investigated the effectiveness of ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma (OAL). Patients and methods: Patients with pathologically confirmed ocular adnexal low-grade non-Hodgkin lymphoma (predominantly mucosa-associated lymphoid tissue, MALT or follicular lymphoma) were included and treated with ultra-low-dose radiotherapy consisting of 2 successive fractions of 2 Gy at our institution between 2019 and 2021. Disease response was assessed clinically and radiographically within 4 months and at 3 to 6-month intervals after treatment. Data collected included rates of overall response, complete response (CR), partial response (PR), lesion size, and acute/chronic ocular toxic effects. Results: Sixteen patients with median age of 63 years (range 23-86 years) were included in the study. The histological subtypes included MALT (11 patients; 69%); follicular lymphoma (2 patients; 12%); Lymphoid hyperplasia (3 patient, 19%). At a median follow-up time of 15.5 months (range 5.0-30.0 months), the overall response rate was 88%, with a CR rate of 75% (n = 12) and a PR rate of 13% (n = 2). The average lesion area was reduced from 117.9 ± 60.4 mm2 before radiation therapy to 38.7 ± 46.0mm2 at initial evaluation post radiation therapy (P = 0.002, n = 16), and to 8.5 ± 21.2 mm2 (P < 0.001 compared with postoperative lesion area) in patients with response at one year (n = 11). Disease progression was noted in 2 patients (12%). The 1-year rates of local progression-free survivals (LPFS) and overall survival (OS) were 85% and 100%, respectively. No distant relapses were observed in any of the patients. No acute or late toxic effects were noted. Conclusion: Ultra-low-dose radiotherapy in patients with OAL is associated with excellent local disease control and long-term survival with no significant acute or late toxicities.
Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma

Yao-Chang Wen,Tzu-Chuan Huang,Wen-Chiuan Tsai,Shiue-Wei Lai

DOI: https://doi.org/10.3390/medicina60050706

2024-04-25

Abstract:Ocular adnexa region (OAR) primary lymphomas are uncommon, accounting for 1-2% of non-Hodgkin lymphomas and 8% of extranodal lymphomas. Extranodal marginal zone lymphoma (EMZL) originates from several epithelial tissues, including the stomach, salivary gland, lung, small intestine, thyroid gland, and ocular adnexa region. Here, we report a 66-year-old female patient who was diagnosed with EMZL of OAR. In consideration of the possible side effect of radiotherapy, such as conjunctivitis, visual acuity impairment, and even retinal complications, she received six cycles of triweekly targeted chemotherapy with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) without radiotherapy. Then, she remained in complete remission up to the present day.
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

Chelsea C Pinnix,Bouthaina S Dabaja,Sarah A Milgrom,Grace L Smith,Zeinab Abou,Loretta Nastoupil,Jorge Romaguera,Francesco Turturro,Nathan Fowler,Luis Fayad,Jason Westin,Sattva Neelapu,Michelle A Fanale,Maria A Rodriguez,Frederick Hagemeister,Hun Ju Lee,Yasuhiro Oki,Michael Wang,Felipe Samaniego,Linda Chi,Bita Esmaeli

DOI: https://doi.org/10.1002/hed.24717

Abstract:Background: The purpose of this study was to report the response to and toxicity of ultra-low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL). Methods: We conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects. Results: Twenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient. Conclusion: Ultra-low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1095-1100, 2017.
The outcome of radiation therapy as a primary treatment in orbital lymphoma: a systematic review

Thalia Puteri Oktariana,Aisha Andriana,Rafiq Sulistyo Nugroho

DOI: https://doi.org/10.5603/RPOR.a2022.0065

2022-09-19

Abstract:Background: The extranodal marginal-zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) is the most common orbital and adnexal lymphomas. Radiotherapy is one of the most preferred treatment options for orbital lymphomas since they are localized and radiation sensitive. The objective of this study is to evaluate how radiation therapy affected the outcome of orbital MALT lymphoma. Materials and methods: PRISMA guideline was used to conduct this systematic review of electronic databases (PubMed, EMBASE and Cochrane Library), then we assessed the quality of evidence of each paper. Results: Twenty-five studies were finally included. 94% studies were intended for definitive therapy and almost all of the studies used external radiation sources. The total doses given to the tumor bed ranged from 4 Gy to 55 Gy and were divided into three groups: ultra-low dose (4-6 Gy), standard-dose (24-30.6 Gy), and high-dose (> 30.6 Gy). 75-90% patients showed CR and local relapse was only reported at 3.5-5%. Higher 5-year PFS was reported in the patients group with lens shielding (90.1% vs. 82.1%) and an increase in Meiboscore after RT courses. Toxicities, including dry eye and cataract, were reported in several patients. Acute toxicities subsided gradually over a few months with artificial tears. The risk of early cataract formation increases in patients who received > 30 Gy and lower in the IMRT group. Conclusion: RT is a successful primary definitive therapy for low-grade orbital MALT lymphoma, with a high survival rate, low recurrence rate, and typically acceptable toxicity.
Identification and quantification of ventricular dysfunction by echocardiography.

S. Rasmussen,B. Corya

Abstract:
High local control and low ocular toxicity using ultra-low-dose "boom-boom" radiotherapy for indolent orbital lymphoma

Sanjna Shelukar,Christian Fernandez,Zeynep Bas,Lydia Komarnicky,Sara E Lally,Carol L Shields,Adam Binder,Pierluigi Porcu,Onder Alpdogan,Ubaldo Martinez-Outschoorn,Wenyin Shi

DOI: https://doi.org/10.21037/cco-22-84

Abstract:Background: The first line definitive treatment for early-stage indolent B-cell lymphoma is radiation therapy (RT). Due to the sensitivity of orbital structures to radiation, ultra-low-dose RT (4 Gy in 2 fractions, "boom-boom") has and been utilized as an attractive option for orbital lymphoma. In this retrospective study, we evaluated the outcome and toxicity of "boom-boom" RT for indolent orbital lymphoma with an emphasis on ophthalmologic toxicity. Methods: This is a retrospective case series with 17 patients with orbital lymphoma who received boom-boom RT at a single tertiary referral center between January 2017 and June 2022. Medical records, imaging and radiation treatment plans were reviewed. Endpoints included response rate, progression, and ocular toxicity per oncologist and ophthalmology reports. Results: A total of 17 patients (12 female and 5 male) with 19 indolent orbital lymphomas were included. Median follow-up was 39 months. Complete, partial, and stable response was achieved in 65%, 24%, and 12% of patients, respectively. Only 1 patient developed local recurrent 47 month after radiation treatment, and was successfully salvaged with standard dose radiation (24 Gy). Five-year distant progression rate is 18%. Oncologist-reported Common Terminology Criteria for Adverse Events (CTCAE) toxicity rates were 6% grade 1 and 0% grade 2+. Ophthalmologist reported 33.3% new post-RT toxicities including dry eye, cataract, and chorioretinal atrophy. There is no significant vision acuity change after RT. Conclusions: "Boom-Boom" RT (4 Gy in 2 fractions) provides excellent control for indolent orbital lymphoma. While minimal toxicity was documented by radiation oncologists, higher rates were noted by ophthalmologists, highlighting the radiosensitivity of orbital structures and potentially underreported ocular toxicity in "boom-boom" and standard regimens. Further prospective randomized studies are needed to better define the outcome and toxicity of ultra-low-dose (4 Gy) RT for ocular lymphoma.
Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal study

Christian Hoffmann,Philipp Rating,Nikolaos Bechrakis,Anja Eckstein,Ekaterina Sokolenko,Leyla Jabbarli,Henrike Westekemper,Christopher Mohr,Claus Schmeling,Andreas Huettmann,Julia von Tresckow,Sophia Göricke,Cornelius Deuschl,Patricia Johansson,Christoph Poettgen,Thomas Gauler,Nika Guberina,Sourour Moliavi,Martin Stuschke,Maja Guberina

DOI: https://doi.org/10.1002/hon.3053

Abstract:We assessed the long-term outcomes and treatment-related adverse effects of patients with Stage I, "orbital-type" lymphomas that were uniformly treated with photons. All consecutive patients diagnosed with low-grade, Ann Arbor Stage IEA orbital lymphoma treated between 1999 and 2020 at our department were retrospectively reviewed. We excluded patients with exclusive conjunctival involvement, typically treated with en face electrons. In order to quantify radiotherapy related side effects we applied the CTCAE criteria, analyzed changes in visual acuity, quantified dry eye symptoms by use of the Ocular Surface Disease Index (OSDI) score and applied the EORTC QLQ-C30 questionnaire for quality of life (QoL) assessment. In total 66 eyes of 62 patients were irradiated with a median dose of 30.6 Gy. The median follow-up was 43.5 months. The predominant histological subtype were MALT lymphomas. No local failure occurred in this cohort. Of nine outfield relapses, six solely occurred in the contralateral eye. The 5- and 10- years distant progression free survival rates (PFS) were 81.4% and 63.5%. The 5- and 10-years overall survival rates were 85.1% and 71.9% without any tumor related death. Of the acute toxicities none was higher than CTCAE grade 1. The predominant late toxicities were dry eyes (21.2%) of CTCAE Grade <2 and radiation induced cataracts (19.7%). During long-term follow up the average visual acuity did not deteriorate. The global QoL was worst before treatment and improved significantly after 24 months (p = 0.007). External beam radiotherapy of "orbital-type" lymphomas with photons is an effective and gentle treatment option with excellent local control rates. From the high control rates the trend to use slightly lower total doses of 24-27 Gy with conventional fractionation is supported. As non-coplanar radiotherapy techniques improved and total doses can slightly be reduced, the current status of radiotherapy as first line therapy is provided.

Stock Control through Video Surveillance in Logistics

Multifocal Lateral and Fourth Ventricular Primary Central Nervous System Lymphoma: Case Report and Literature Review.

A rare type of left atrial dissection.

Accounting for voice-quality variation

[Rabies specific IgM- and IgG-antibody response in persons immunized with HDCS vaccine according to the Essen postexposure vaccination schedule (author's transl)].

Treatment Outcomes of Low-grade Lymphoma of the Orbit

Introducing Brian Boycott and Heinz Wassle, the 1999 recipients of the proctor medal.

Ultra-low dose radiotherapy in the management of low-grade orbital lymphomas

POSSIBLE DANGER OF ASPIRIN THERAPY IN PRESENCE OF MIGRAINE

Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?

[Secondary orbital lymphoma]

Orbital metastasis from thyroid cancer: a case report and review of the literature

Orbital lymphoma

Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection.

Ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study

Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

The outcome of radiation therapy as a primary treatment in orbital lymphoma: a systematic review

Identification and quantification of ventricular dysfunction by echocardiography.

High local control and low ocular toxicity using ultra-low-dose "boom-boom" radiotherapy for indolent orbital lymphoma

Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal study